Previous 10 | Next 10 |
Summary Ascendis is a mid-cap commercial biotech based in Denmark. Currently, it trades around $6.7B market cap, and the company holds $900M cash. Skytrofa (TransCon hGh) is Ascendis' lead approved agent for pediatric growth hormone deficiency (GHD), where the commercial update was luke...
Summary Many dividend investments remain oversold and are great opportunities. I invest for income and it allows me to control my retirement outlook. We look at two excellent opportunities. Co-produced with Treading Softly. The famous Charles Dickens book, A Tale...
Summary Presenting our 2022 year-end review of our 8% Income Portfolio. This high-income portfolio earned over $29,000 in distributions (including year-end special distributions) amounting to over 14% yield-on-cost basis. The portfolio had a loss of -12.5% in 2022, compared to -18.2...
Summary Closed-end funds are great income investments thanks to tax laws and tradition. Being required to pay out most of their taxable gains explains a lot about how CEFs act. CEFs can be great income investments. Co-produced with Beyond Saving. Introduction W...
Summary 2022 was a year to forget, while most believe 2023 will begin with the same issues that took the equity and bond markets well into bear market territory last year. That is, a hawkish Federal Reserve that doesn't want to let up on strangling inflation into submission while draini...
Summary We share data on over 50 big-yield healthcare investments, including individual stocks, REITs, closed-end funds ("CEFs") and bonds. We dive deeper into three specific attractive big-yield opportunities that also have healthy upside potential. We begin with a special focus on...
Summary The iShares Biotechnology ETF (IBB) is down -12.9% year-to-date but the Tekla biotech equity CEFs are down even more despite NAVs that are holding up extremely well. The result is that the Tekla biotech CEFs (HQH) and (HQL) keep dropping to lower-and-lower valuations with HQH no...
Tekla Healthcare Investors ( NYSE: HQH ) declares $0.39/share quarterly dividend , -2.5% decrease from prior dividend of $0.40. Forward yield 8.3% Payable Dec. 30; for shareholders of record Nov. 25; ex-div Nov. 23. See HQH Dividend Scorecard, Yield Chart...
Summary For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promises high distributions and reasonable total returns. Closed-end funds are generally characterized by higher volatility and deeper drawdowns than the...
Summary THW is still continuing with a steady monthly payout and generating close to double-digit yield, and it is relatively better protected from market risk. THW failed to grow during the past six months, as its major holdings failed to generate price growth. However, total ret...
News, Short Squeeze, Breakout and More Instantly...
Tekla Healthcare Investors Company Name:
HQH Stock Symbol:
NYSE Market:
2024-04-22 03:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-02 07:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-23 06:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...